Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
Key claim: A phase II single-arm multicenter trial (AVENHIR) is evaluating the efficacy and safety of azacitidine combined with venetoclax specifically in patients with higher-risk chronic myelomonocytic leukemia.
Abstract
Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia
Why this matters
Higher-risk CMML has limited effective therapies beyond hypomethylating agent monotherapy, and outcomes remain poor. AVENHIR tests whether the AML-established azacitidine + venetoclax doublet translates to CMML, where monocytic differentiation and distinct BCL-2 family dependencies may alter response. Positive results would establish a new standard backbone for higher-risk CMML and differentiate this subtype’s treatment trajectory from classical MPNs.